Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Conditions
Interventions
Temanogrel
Placebo
Locations
6
United States
Yale University
New Haven, Connecticut, United States
Johns Hopkins Asthma and Allergy Center
Baltimore, Maryland, United States
UPMC Arthritis and Auotimmune Clinic
Pittsburgh, Pennsylvania, United States
Ninewells Hospital & Medical School
Dundee, Scotland, United Kingdom
Royal United Hospitals Bath
Bath, United Kingdom
Salford Royal Hospital
Salford, United Kingdom
Start Date
November 3, 2021
Primary Completion Date
September 2, 2022
Completion Date
September 2, 2022
Last Updated
December 22, 2023
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions